Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.24 - $1.47
Previous CloseN/A
Volume22.63K
Average Volume (3M)2.42M
Market Cap
$86.75M
Enterprise Value-$788.97K
Total Cash (Recent Filing)$38.35M
Total Debt (Recent Filing)$1.38M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Nov 12, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding71,109,510
10 Day Avg. Volume2,523,733
30 Day Avg. Volume2,419,924
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue-0.12
Enterprise Value/Gross Profit-0.12
Enterprise Value/Ebitda0.02
Forecast
1Y Price Target
$2.92Price Target Upside131.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOvid's preclinical characterization suggests OV329 is significantly more potent than existing treatments and offers a preferable safety profile.
Financial PerformanceOvid's valuation does not yet include potential contributions from its KCC2 activators, suggesting future clinical success could drive significant upside.
Strategic DevelopmentsThe development of new drug candidates targeting psychosis in Parkinson's and Lewy body dementia could address unmet medical needs and expand market opportunities.
Bears Say
Development ChallengesResearch and development expenses have seen a slight decrease, which might indicate a slowdown in certain development activities.
Financial NeedsThe company needs cash.
Market UncertaintyHistorical data from similar companies suggest that Phase 1 data alone may not significantly impact OVID shares, though a re-rating remains possible with positive results.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $1.47 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $86.75M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Nov 12, 2025 which is in 75 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Aug 13, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.098.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.14.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 71,109,510 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went up 56.364%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.92 (131.75% Upside)
$2.92 (131.75% Upside)
Blogger Sentiment
Bearish
OVID Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 11.3%
Last 30 Days ▲ 11.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.15%
12-Months-Change
Fundamentals
Return on Equity
-52.77%
Trailing 12-Months
Asset Growth
-34.43%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Stock 12 Month Forecast
Average Price Target
$2.92
▲(131.75% Upside)
Technical Analysis
Ownership Overview
5.36% Insiders
7.53% Mutual Funds
31.35% Other Institutional Investors
51.95% Public Companies and
Individual Investors